CD38 and Miyoshi myopathy: Other single‐center real‐life experiences or case series have reported that CMV reactivation can be frequent in anti‐CD38 agent treated MM subjects in up to 38% of cases35, 36, 40, 41; however, symptoms are commonly mild with fever, while CMV disease development is rare.40